| Scorecard |
|---|
|
1 / 5 Stars
|
|
Lipper
1
1
5
1
2
|
|
Zacks Investment Research
1
(Strong Buy)
|
|
Standard & Poor's
2 / 5 Stars
|
|
TheStreet.com
A-
(Buy)
|
#28 in Health
U.S. News evaluated 38 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.
Performance
The fund has returned 36.87 percent over the past year, 16.95 percent over the past three years, 7.98 percent over the past five years, and 8.05 percent over the past decade.
| Trailing Returns | Updated 05.31.2013 |
|---|---|
| Year to date | 27.4% |
| 1 Year | 36.9% |
| 3 Years (Annualized) | 16.9% |
| 5 Years (Annualized) | 8.0% |
| 10 Years (Annualized) | 8.1% |
Summary
The investment seeks long-term growth of capital. The fund normally invests at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries, generally, with an emphasis toward companies engaged in cancer research and drug development. It is non-diversified.
Fees
Fees are Average compared to funds in the same category.
Kinetics Medical Fund has an expense ratio of 1.64 percent.
Risk
Risk is Average compared to funds in the same category according to Morningstar.
